X SCRIBE THERAPEUTICS
LIVE

Serial Number

97473476

Owner

Scribe Therapeutics Inc.

Attorney

John Paul Oleksiuk

Filing Date

Jun 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

X SCRIBE THERAPEUTICS Trademark

Serial Number: 97473476

X SCRIBE THERAPEUTICS is a trademark filed by Scribe Therapeutics Inc. on June 23, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Scribe Therapeutics Inc. (12 trademarks)

Alameda, CA 94501

Entity Type: 03

Trademark Details

Filing Date

June 23, 2022

Registration Date

Not Registered

Published for Opposition

April 25, 2023

Goods & Services

Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cance

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 15, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 15, 2025 EX5G
SOU EXTENSION 5 FILED
Dec 14, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 14, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2025 EXRA
SOU EXTENSION 4 GRANTED
Dec 9, 2025 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 9, 2025 AITU
SOU EXTENSION 4 FILED
Jun 18, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 18, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jan 2, 2025 EPPA
SOU EXTENSION 3 GRANTED
Dec 16, 2024 EX3G
SOU EXTENSION 3 FILED
Dec 16, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 15, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jun 11, 2024 EX2G
SOU EXTENSION 2 FILED
Jun 11, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 11, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 10, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 10, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 10, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 20, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 25, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 5, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 16, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 16, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 16, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 16, 2023 CNEA
ASSIGNED TO EXAMINER
Mar 9, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 13, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2022 NWOS
NEW APPLICATION ENTERED
Jun 27, 2022 NWAP